About Vicebio
Vicebio is a Healthcare company based in London (United Kingdom) founded in 2019, and was acquired by Sanofi in July 2025. Vicebio is focused on respiratory disease prevention through innovative vaccines. It operates on a HealthTech model. Vicebio has raised $100 million across 1 funding round from investors including Sanofi, TCG Crossover and Avoro Capital Advisors. Its chief executive is Emmanuel Hanon. Vicebio offers products and services including Molecular Clamp Vaccines and RSV/hMPV Bivalent Vaccine. Its focus areas include Biotechnology and Vaccine Development. Its legal entity is VICEBIO LIMITED. Its competitors include Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Vicebio is engaged in the development of next-generation vaccines targeting respiratory diseases. Utilizing its proprietary Molecular Clamp technology, the company is positioned to deliver broad protection, ready-to-use formulations, and high manufacturability. A robust pipeline is being advanced to address critical global health challenges in the respiratory sector. The organization is driven by a commitment to scientific innovation and patient impact, with solutions aimed at revolutionizing vaccine development for multipathogen respiratory conditions.
- Headquarters London, United Kingdom
- SectorsHealthcare
- Email••••••••
- Website vicebio.com
- Social LinkedIn
- Acquired by Sanofi (Jul 2025)
- Legal Name Vicebio Limited
- Date of Incorporation 14 Sep, 2018
- Jurisdiction LONDON, UNITED KINGDOM
Products & Services of Vicebio
Vicebio offers a comprehensive portfolio of products and services, including Molecular Clamp Vaccines and RSV/hMPV Bivalent Vaccine.
Vaccines are developed using Molecular Clamp technology platform.
Bivalent vaccine is advanced for respiratory disease prevention.
Funding Insights of Vicebio
Vicebio has successfully raised a total of $100M through 1 strategic funding round. The most recent funding activity was a Series B round of $100 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $100M
- Total Rounds 1
- Last Round Series B — $100M
- First Round $100M
(Sep 2024)
- Investors Count 5
All 1 funding rounds of Vicebio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2024 | $100M | Series B | – | TCG Crossover |
6 investors in total: 6 institutional.
Investors in Vicebio
Vicebio has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Sanofi, TCG Crossover and Avoro Capital Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | tcgcrossover.com | - | |
Venture capital fund focused on biotechnology startups | – | avorocapital.com | New York, United States | |
A life sciences investment firm focused on novel therapeutics is operated. | 2011 | venbio.com | San Francisco, United States | |
UniQuest is engaged in commercialising intellectual property and innovation. | – | uniquest.com.au | Brisbane, Australia | |
Early-stage life science focused VC firm investing in geographies such as Europe and the US | – | medicxi.com | London, United Kingdom | |
Pharmaceutical and nutraceutical products are developed across seven therapeutic areas. | 1973 | sanofi.com | Paris, France |
Investor details for Vicebio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vicebio
1 people are tracked at Vicebio (1 in leadership).
| Name | Role | Group |
|---|---|---|
Emmanuel Hanon | CEO | Leadership |
Complete people profiles for Vicebio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Vicebio
3 dated milestones of Vicebio across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Vicebio is founded.
- Funding First funding round of $100.0M.
- Exit Acquired by Sanofi.
Competitors of Vicebio
Vicebio has 9 listed competitors in our database, 8 of them funded. They include Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| chimerix.com | 2002 | Durham, United Kingdom | $95.23M | 72 | Antiviral oral therapeutics are developed for infectious diseases and cancers. | |
| hookipapharma.com | 2011 | Vienna, Austria | $133.72M | – | Developer of immunotherapies for the treatment of infectious diseases and cancer | |
| novavax.com | 1987 | Gaithersburg, United States | – | 184 | Novel vaccines are developed using nanoparticle and matrix adjuvant technology. | |
| generatebiomedicines.com | 2018 | Somerville, United States | $643M | 286 | Developer of novel protein-based therapeutics using machine learning and biological engineering | |
| vbivaccines.com | 2001 | Cambridge, United States | $65.07M | 13 | VBI Vaccines is engaged in developing vaccines and immunotherapeutics. | |
| briibio.com | 2018 | San Francisco, United States | $415M | 68 | Developer of biologics to treat hepatitis B infection | |
| molecularpartners.com | 2004 | Zurich, Switzerland | $59.94M | – | Therapeutic solutions for diseases are developed using DARPin technology. |
Detailed competitors of Vicebio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as Vicebio (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vicebio
Complete news archive for Vicebio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vicebio
Vicebio was founded in 2019 and raised its 1st funding round 5 years after it was founded.
Vicebio is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Emmanuel Hanon is the current CEO of Vicebio.
Vicebio is a funded company, having raised a total of $100M across 1 funding round to date. The company's 1st funding round was a Series B of $100M, raised on Sep 2024.
Vicebio is engaged in the development of next-generation vaccines targeting respiratory diseases. Utilizing its proprietary Molecular Clamp technology, the company is positioned to deliver broad protection, ready-to-use formulations, and high manufacturability. A robust pipeline is being advanced to address critical global health challenges in the respiratory sector. The organization is driven by a commitment to scientific innovation and patient impact, with solutions aimed at revolutionizing vaccine development for multipathogen respiratory conditions.
Vicebio's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Vicebio offers Molecular Clamp Vaccines and RSV/hMPV Bivalent Vaccine.
Vicebio has 6 investors. Key investors include Sanofi, TCG Crossover, Avoro Capital Advisors, venBio, and UniQuest.
Vicebio operates through Vicebio Limited.
Yes. Vicebio was acquired by Sanofi in July 2025.